Lipocine Inc., a specialty pharmaceutical company, announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The company focuses on developing novel oral therapeutics, including treatments for postpartum depression, major depressive disorder, epilepsy, and other conditions. Their FDA-approved drug TLANDO treats testosterone deficiency in adult males. This presentation offers investors insight into Lipocine’s development pipeline and future prospects. The event will be accessible both in person and virtually, with a webcast available for 90 days after the presentation.
Cryptocurrency markets saw a general decline with major coins like Bitcoin dropping 2.03% to $77,737 and Ethereum falling 1.66% to $2,457.87. Other notable cryptocurrencies such as Binance Coin, XRP, and Dogecoin also experienced significant decrease...
Alphabet's shares fell 7.46% over the past month, underperforming the Nasdaq despite strong fundamentals like 24.23% revenue growth and robust AI investments. The company leads in search, video, cloud, and AI, with Google Cloud revenue up 82% year-ov...
On September 8, XRP spot ETFs attracted about $1.55 million in net inflows, making them the only crypto ETFs to see daily gains. In contrast, ETFs for Bitcoin, Ethereum, Solana, and Hyperliquid experienced net withdrawals on the same day. This highli...
Duke Energy (DUK) is positioned as a solid long-term investment due to its regulated profits from essential infrastructure and a growing dividend yield of 3.6%. The company benefits from an expansive grid and nuclear fleet, which support rising elect...
Equinix has named DD Dasgupta as its new Chief Marketing Officer. Dasgupta brings over 25 years of experience in digital infrastructure and has been with Equinix since 2024, previously leading product and solution marketing. His appointment comes as ...
